Several possible studies
Story checked
Xenon Showcases New 48-Month Azetukalner OLE Study Data in (opens in a new tab)
globenewswire.com · 2025-12-05
Short answer
Several possible studiesStudy not confirmed.
Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
Xenon Showcases New 48-Month Azetukalner OLE Study Data in
globenewswire.com · 2025-12-05
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Multiple potential source studies identified.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
View article claimsSearch result
Several studies could fit.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 4Not checkedXenon said interim 48-month data from its ongoing X-TOLE open-label extension study of azetukalner in patients with focal onset seizures showed more than 90% monthly reductions in seizure frequency, with 38% of participants achieving at least 1 year of seizure freedom.View evidenceHide evidence
As stated90.9% monthly reduction; 38.2% attained ≥12 months of seizure freedom
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 4Not checkedA new analysis of the X-TOLE OLE suggested that seizure freedom can be attained and, if lost, regained with long-term azetukalner treatment, even in patients with difficult-to-treat disease.View evidenceHide evidence
As stated69.7% regained ≥6 months and 57.6% regained ≥12 months of subsequent seizure freedom among those with a breakthrough seizure
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 3 of 4Not checkedXenon highlighted four real-world epilepsy posters suggesting a significant burden of depression and ASM titration among people living with epilepsy, including a poster on depression’s impact on outcomes and treatment patterns in newly diagnosed epilepsy.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 4 of 4Not checkedThe company also reported new pre-clinical Dravet syndrome data suggesting XPC-837 may improve motor function through NaV1.1 potentiation.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Europe PMC, Crossref · 15 candidate papers
Interim analysis of the long-term efficacy and safety of azetukalner in an ongoing open-label extension study following a phase 2b clinical trial (X-TOLE) in adults with focal epilepsy.
Epilepsia Open · 2025 · PubMed, Europe PMC
Wide Range of Cenobamate Doses Associated With Initial Seizure Freedom in Patients With Uncontrolled Focal Seizures: Post-hoc Analysis of a Phase 3, Multicenter, Open-Label Study (P12-9.003)
Neurology · 2025 · Crossref
From Retigabine to Azetukalner: Reviving Voltage-Gated Potassium Channels for Epilepsy Therapy.
2026 · Europe PMC
Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial.
JAMA Neurology · 2023 · PubMed, Europe PMC
Experience of perampanel monotherapy beyond initial titration to achieve seizure freedom in patients with focal‐onset seizures with newly diagnosed or currently untreated recurrent epilepsy: A post hoc analysis of the open‐label Study 342 (FREEDOM)
Epilepsia Open · 2022 · Crossref